Saturday, October 23, 2021

AHS extends vaccination deadline for staff. Alberta Canada Health Department with over 100,000 staff rolls back deadline. Remain Firm!

Alberta Health Services is pushing back its vaccination deadline for its 108,000 staff until November 30.

The AHS originally set October 31 as the deadline for staff to be double-vaxxed or face discipline, including being placed on unpaid leave.

“We stand by the mandatory immunization policy and it will be fully implemented,” said AHS president and CEO, Dr. Verna Yiu...


Anonymous said...

Oklahoma City Police Department DROPS COVID-19 vaccine requirement for new hires, recruits.

Anonymous said...

Amen! Keep up the quiet resistance. Keep citing the data, particularly those that question the efficacy of the currently available vaccines, and those that show the efficacy of the alternative: early outpatient treatment.

As to that, a newly released real-world study from Australia, using data collected when the delta strain was predominant (June-September this year), showed a statistically significant benefit of ivermectin triple therapy (ivermectin, doxycycline, and zinc) in patients with COVID symptoms and positive PCR. Treatment was started within 2 days of a positive PCR result and continued for up to 10 days.

The hospitalisation rate in the treated group of 600 patients was less than 1% (5 patients), whereas it was 11.5% (70 patients) in a contemporaneous group of 600 patients who were not treated. There were no deaths in the treated group but 6 deaths (1%) in the control group.


Anonymous said...

... and here's a fun bit from the Australian study:

"The major differences in admission to hospital and death following ITT [ivermectin triple therapy: ivermectin + doxycycline + zinc] therapy compared to contemporary controls is consistent with the large and increasing body of data measuring the impact of ivermectin-combination therapy.1–3 The results from this study invites comparison with recently announced data by Merck from a study of their re-cycled antiviral polymerase inhibitor, Molnupiravir. The Merck study with 385 treated patients involved a similar group to that treated in the current Australian study judged by near-identical hospital admission and mortality rates in both control groups. In the Merck study, the
hospital admission rate was halved (7.3% of treated patients) with no deaths, similar to data for the “first cousin” of Molnupiravir, Favipiravir, which is used extensively in Russia. The important point is that the admission rate in the Merck study is 8-fold greater than the 90% reduction in hospital admissions recorded in the current ITT study (P<0.0001). The public health impact of these findings with a cheap, safe and available therapy, in terms of reduction of load on a health system that will be further stressed as country borders are re-
opened, cannot be ignored."


Anonymous said...

... and speaking of Merck, look what else they've been up to!

TITLE: An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats

AUTHORS: Martijn A Langereis, Irina C Albulescu, Judith Stammen-Vogelzangs, et al.

JOURNAL: NPJ Vaccines. 2021 Oct 20;6(1):122.
doi: 10.1038/s41541-021-00390-9.

PubMedID: 34671047


Early in the SARS-CoV-2 pandemic concerns were raised regarding infection of new animal hosts and the effect on viral epidemiology. Infection of other animals could be detrimental by causing clinical disease, allowing further mutations, and bares the risk for the establishment of a non-human reservoir. Cats were the first reported animals susceptible to natural and experimental infection with SARS-CoV-2. Given the concerns these findings raised, and the close contact between humans and cats, we aimed to develop a vaccine candidate that could reduce SARS-CoV-2 infection and in addition to prevent spread among cats.

Here we report that a Replicon Particle (RP) vaccine based on Venezuelan equine encephalitis virus, known to be safe and efficacious in a variety of animal species, could induce neutralizing antibody responses in guinea pigs and cats….

[From the text: "we utilized an Alphavirus-based Replicon technology derived from the attenuated TC-83 strain of Venezuelan equine encephalitis virus (VEEV) to express the SARS-CoV-2 S protein.”]

The design of the SARS-CoV-2 spike immunogen was critical in developing a strong neutralizing antibody response. Vaccination of cats was able to induce high neutralizing antibody responses, effective also against the SARS-CoV-2 B.1.1.7 variant. [This is the alpha variant.]

Interestingly, in contrast to control animals, the infectious virus could not be detected in oropharyngeal or nasal swabs of vaccinated cats after SARS-CoV-2 challenge. Correspondingly, the challenged control cats spread the virus to in-contact cats whereas the vaccinated cats did not transmit the virus.

The results show that the RP vaccine induces protective immunity preventing SARS-CoV-2 infection and transmission. These data suggest that this RP vaccine could be a multi-species vaccine useful to prevent infection and spread to and between animals should that approach be required.


The full text of this paper is available here:

Anonymous said...

Evidence Clearly Shows Deaths are Increasing Worldwide After COVID-19 Shots!

Anonymous said...

1.) Sweden Suspends Moderna Shot Indefinitely After Vaxxed Patients Develop Crippling Heart Condition.

2.) Fauci Funded 'Cruel' Puppy Experiments Where Sand Flies 'Eat Them Alive'; Vocal Cords Severed. Evil Man!

Anonymous said...

Dr. Naomi Wolf: CDC COVID Data Is Actually Farmed Out to Non-Profit with 'Ties to Gates' (VIDEO)

Anonymous said...

This is meant to be satirical but it's too true to be funny :(

Anonymous said...

Military, Federal Employees and Contractors File Class-Action Lawsuit against Pentagon over Vaccine Mandates!